Objective: The aim of this study was to determine whether endovascular or open revascularization provides an advantageous approach to symptomatic peripheral arterial disease (PAD) over the longer term. Summary of Background Data: The optimal revascularization strategy for symptomatic lower extremity PAD is not established. The amputation-free survival benefit associated with an endovascular revascularization was more pronounced in patients with congestive heart failure or ischemic heart disease than in those without (P ¼ 0.021 for interaction term). The rate of subsequent intervention at 30 days was 7.4% greater for the endovascular vs the open revascularization cohort. At 4 years, this difference remained stable at 8.6%. Conclusions: Using population-based data, we demonstrate that an endovascular approach is associated with improved amputation-free survival over the long term with only a modest relative increased risk of subsequent intervention.
L ower extremity peripheral arterial disease (PAD) is the most underdiagnosed cardiovascular disorder in the United States and affects over 12 million individuals. [1] [2] [3] [4] [5] Patients with symptomatic PAD classically experience intermittent claudication (ie, exertional muscular calf or thigh pain during walking that resolves with rest), with progression to critical limb ischemia (ie, rest pain, ulceration, gangrene necrosis) in up to 25% of patients. 6 Treatment for symptomatic patients who fail conservative management has traditionally been surgical revascularization. However beginning in the 1980s, patients are more often offered a less invasive endovascular approach, which is now widely utilized. 7, 8 The optimal revascularization strategy for symptomatic lower extremity PAD is not well established. Existing randomized controlled trials comparing endovascular with open revascularization for lower extremity PAD have been limited by patient selection and the inability to generalize findings beyond specialized centers. [9] [10] [11] [12] [13] [14] [15] [16] Given the lack of high-quality comparative data, 2 additional randomized controlled trials comparing open with endovascular intervention for lower extremity PAD have recently begun enrolling subjects. 17, 18 However, because endovascular therapy has become so prominent, these trials may have difficulty enrolling patients because patients prefer ''less invasive'' options making the establishment of clinical equipoise challenging. 19 Moreover, these studies may take several years to complete and thus the eventual results may not reflect contemporary clinical practice.
In this evaluation, our objective is to conduct a comparative evaluation of open vs endovascular treatment of lower extremity revascularization using nationally representative Medicare data. We examine immediate as well as long-term outcomes including rates of subsequent intervention to determine whether the relative benefit of these interventions changes over time.
METHODS

Data Acquisition and Cohort Selection
We analyzed data from the Centers for Medicare & Medicaid Services Chronic Conditions Warehouse for 2006 to 2009, a longitudinal 5% sample representative of Medicare beneficiaries nationally. 20 Records include patient demographics, clinical characteristics, Medicare enrollment data, and facility and provider claims. We selected all inpatients with a diagnosis for PAD using International Classification of Disease, ninth revision (ICD-9) codes, as previously described. 21, 22 We selected patients over age 65 years who underwent an open or endovascular lower extremity revascularization procedure (see Table 1S , Supplemental Digital Content 1, http://links.lww.com/SLA/A981, which displays respective codes). [22] [23] [24] We excluded patients who had incomplete data from enrollment in Medicare Part A and Part B, coverage by a Medicare health maintenance organization (HMO), railroad benefits in the year before surgery and trauma-related revascularization. 22 
From the
Primary Outcome
Our primary outcome was the incidence of major amputation or death. We classified amputation as major when performed at the transtibial level or above as previously described. 7, 24, 25 We did not include amputations at the metatarsal level or below, as these do not represent failures of limb salvage. 7 Because the purpose of revascularization is to preserve limb and life, any major amputation or death represents a failure of the procedure consistent with existing literature. 9 
Variables
Explanatory variables are listed in Table 1 . We identified patients with diabetes using validated methodology published by Hebert et al. 26 Severity of lower extremity PAD was dichotomized into claudication or critical limb ischemia based upon the diagnosis on admission (see Table 1S , Supplemental Digital Content 1, http:// links.lww.com/SLA/A981, which displays respective codes). 27 We examined validated Elixhauser comorbidities and defined cancer as a composite variable of lymphoma and metastatic cancer. 28 Because The standardized differences are reported as percentages; a difference of less than 10% indicates a relatively small imbalance. Endo indicates endovascular; RA, rheumatoid arthritis; RUCA, rural urban commuting area; SD, standard deviation.
the rate of endovascular interventions for PAD increased systematically over the study period, analysis adjusted for year of procedure. Patient's residence and hospital location were classified using RuralUrban Commuting Area (RUCA) codes. 29, 30 Origin of admission included: Referral (ie, referral from physician, clinic, or HMO), transfer (ie, transfer from hospital, skilled nursing facility, or another health care facility), or the emergency department.
Propensity Score
Given the differences in baseline characteristics between groups receiving endovascular and open procedures, we used propensity score matching to ensure that patient cohorts had similar covariate distribution. We first estimated the propensity score as the probability of receiving an endovascular intervention, conditioned on all preoperative characteristics, and their interactions with renal failure, diabetes, and presence of critical limb ischemia. 31 Matching was performed using a 1 : 1 protocol without replacement (nearest neighbor approach) with a caliper width equal to 0.25 of the standard deviation of the propensity score. 32 We assessed balance between the groups before and after matching using standardized differences; values less than 10% for a given variable denote a relatively small imbalance. 33 We present descriptive statistics for both unmatched and matched cohorts; all subsequent analyses are on matched cohorts.
Statistical Analysis
Chi-square tests evaluate unadjusted 30-day postoperative amputation and mortality rates between patient groups. KaplanMeier curves depict overall survival and amputation-free survival by procedure type, and log-rank tests identify differences between groups. We censored patients without incidence of amputation or death on December 31, 2009. We evaluated predictors of amputationfree survival using a multivariable Cox proportional hazards model. Hazard ratios (HRs) and 95% confidence intervals (95% CIs) are presented with 2-sided P values (alpha ¼ 0.05).
Interactions
We examined interactions between procedure type (endovascular and open) and common morbidities in the PAD population (extent of disease, diabetes, congestive heart failure/ischemic heart disease [CHF/IHD], and renal failure) 34 to assess whether a significant disease burden moderates the association between procedure type and outcome. We also examined selected interactions between diabetes and comorbid conditions-history of myocardial infarction (MI), CHF/IHD, stroke, and eye disease-to explore whether diabetes was associated with diminished amputation-free survival.
Secondary Interventions
We identified endovascular (ie, angiogram, thrombolysis, angioplasty, stent-placement, atherectomy) and open (ie, thrombectomy, open-bypass) interventions that occurred subsequent to the qualifying procedure (see Table 2S , Supplemental Digital Content 1, http://links.lww.com/SLA/A981, which displays respective codes) and determined the time to first intervention (Kaplan-Meier life tables) and the frequency of subsequent interventions. The data do not indicate laterality of secondary procedures. Assuming that the frequency of subsequent intervention in the contralateral leg was equivalent in both the open and endovascular cohorts, we used the difference in intervention rates between the groups as a proxy measure of reintervention in the ipsilateral limb.
Sensitivity Analysis
To determine whether our estimation of the treatment effect is valid using propensity score matching, we repeated the analysis using (1) propensity score standardized mortality ratio (SMR) weighting estimation and (2) propensity score stratification by quintiles, and compared these results with those obtained by matching. 35 
RESULTS
Study Sample
A total of 14,685 patients met sample inclusion criteria. Of these, 8206 (55.9%) underwent endovascular and 6479 (44.1%) underwent open revascularization. In the unmatched cohort, patients who underwent endovascular treatment were more often female, more frequently had comorbid conditions such as diabetes and renal failure, and less frequently had severe vascular disease manifested by critical limb ischemia. The numeric differences between cohorts with regard to these factors were small, suggesting that similar patients were treated with both techniques (Table 1 ). In the matched cohort, standardized differences in measured variables were well below 10%. The C-statistic for the propensity score logistic regression model was 0.627. The mean follow-up time for patients in the matched cohort was 618 days for endovascular and 597 days for open intervention. Table 2 summarizes the 30-day postoperative amputation and mortality rates after lower extremity revascularization in propensity score matched cohorts. Patients undergoing an endovascular procedure experienced early amputation-free survival advantage (7.4 vs 8.9%, P ¼ 0.002) driven by a diminished mortality (5.3% mortality vs 6.7%, P ¼ 0.001); there were no significant differences in early Figure 1 shows 4-year amputation-free survival by procedure (panel A) and 4-year survival by procedure (panel B) using matched cohorts. Within 1 year, an estimated 24.8% of endovascular and 29.4% of open patients either died or underwent amputation. This 5% differential persisted for the study duration; at 4 years, an estimated 48.6% of endovascular and 54.0% of open patients experienced amputation or death (P < 0.001).
Short-term Outcomes
Long-term Outcomes
Comparing amputation-free ( Fig. 1 A) with overall survival (Fig. 1 B) , the majority of events are attributable to death rather than amputation; at 4 years, only an estimated 3.1% of endovascular patients vs 4 .2% of open patients underwent amputation. 
Amputation-free Survival
Interactions
The majority of comorbidities did not influence relative outcomes (endovascular conferring a slight advantage, regardless of diabetes, renal failure, or critical limb ischemia) except for CHF or IHD. Specifically, in patients with CHF or IHD, the advantage of an endovascular intervention was enhanced (HR: 0.80, 95% CI: 0.75-0.85) (see Figure 1S , Supplemental Digital Content 1, http://links. lww.com/SLA/A981, which displays survival curves for interactions). In addition, tested interactions between diabetes with history of MI, stroke, and eye disease were not significant (P > 0.05).
Subsequent Interventions
Secondary interventions were relatively more common after endovascular than open repair in matched patients (Table 4) . During the first 30 days, patients who had an initial endovascular revascularization underwent subsequent intervention 7.4% more often than open patients. The relative rate of subsequent intervention did not further increase over time; at 4 years, the rate of subsequent intervention was 8.6% higher for endovascular vs open patients. Absolute rates of subsequent interventions (unadjusted for contralateral interventions) are provided in Table 3S , Supplemental Digital Content, http:// links.lww.com/SLA/A981, for reference. Interestingly, the majority of patients who underwent a subsequent intervention following either procedure did so only once (endovascular cohort 60.4%, open cohort: 58.8%).
Sensitivity Analysis
We found similar results after repeating the multivariable Cox proportional hazards model analysis predicting amputation-free survival using SMR weighting (endovascular vs open revascularization HR: 0.84; 95% CI: 0.80-0.88) and propensity score stratification by quintiles (endovascular vs open revascularization HR: 0.84; 95% CI: 0.74-0.95) (see Table 4S and 5S, Supplemental Digital Content 1, http://links.lww.com/SLA/A981, which displays results of Cox proportional hazards model analyses and propensity score quintiles respectively).
DISCUSSION
Our results indicate that in a cohort of Medicare beneficiaries with symptomatic lower extremity PAD, endovascular treatment is associated with improved amputation-free survival compared with an open surgery, particularly among patients with congestive heart failure or ischemic heart disease. This benefit is pronounced in the short term, persists over the long term, and is largely driven by an early differential in mortality. We also examined the frequency of subsequent interventions and found that they are somewhat more frequent after endovascular interventions during the first year, but thereafter the differential between the 2 cohorts remains constant. We used propensity score matching to equalize the patient cohorts.
We found that in the first year, patients who underwent an endovascular procedure had lower risk of amputation or death than open patients (24.8 vs 29.4%). Furthermore, we found that the early amputation-free survival advantage in the endovascular procedure persisted at 4 years. Our findings contrast with those reported in the BASIL trial, the most prominent randomized controlled trial to date. 9 In BASIL, there was no difference in amputation-free survival overall, and when investigators examined patients 2 years beyond randomization, they found that open surgery was associated with a decreased risk of amputation or death. 9 Three phenomena may explain the contrast between our results and those observed in BASIL. First, endovascular technology and surgical technique have improved over time, and the BASIL trial (1999 to 2004) predates our study period. Second, we studied patients with claudication and FIGURE 1. A, Four-year amputation free survival by procedure type and B, 4-year survival by procedure type. Endo, endovascular. critical limb ischemia, whereas the BASIL trial included only patients with severe limb ischemia albeit our findings in the limb threat cohort revealed an advantage of endovascular intervention. 7, 36, 37 Third, distinct study populations may explain the difference: The BASIL trial was conducted in the United Kingdom with patients meeting specific inclusion criteria and intense follow-up, and our dataset is composed of older adults treated as part of usual practice in the United States.
We hypothesized that patients with common, systemic comorbidity and severe vascular disease would be less likely to tolerate an open procedure than those without comorbidity. We also hypothesized that the relative outcome of the 2 interventions might be influenced by conditions such as diabetes or renal failure because of their effect on disease anatomy such as increased calcification, or that the differential in outcomes would be altered in patients with limb threat vs claudication related to extent of disease. To test this, we evaluated interactions between procedure type and select comorbidity burden in predicting outcomes. These hypotheses were largely unsupported, although we found partially consistent results for patients with CHF/IHD. Specifically, patients with CHF/IHD had a decreased risk of amputation or death after an endovascular procedure compared with an open procedure; patients without CHF/IHD did not experience the same benefit from an endovascular approach. Remarkably, the lack of significance for the remainder of tested interactions shows that comorbidity did not alter the benefit associated with an endovascular approach. It appears that, although these comorbid conditions are associated with worse overall amputation-free survival, the advantage of an endovascular procedure is consistent across patient populations.
Historically, and consistent with our findings, long-term mortality in patients with symptomatic PAD, particularly in patients with critical limb ischemia, is very high ranging from 40 to 70% at 5 years. 10, 36, [38] [39] [40] [41] However, over the short term, we found a strikingly high perioperative mortality rate after revascularization, regardless of the intervention used. This was particularly so in patients with critical limb ischemia: 6.5 and 8.3% of patients died within 30 days of an endovascular or open procedure, respectively. These findings contradict the common belief that minimally invasive approaches are associated with insignificant morbidity and mortality. Our results highlight that in a real-world setting, the prognosis after lower extremity revascularization for symptomatic PAD is poor, regardless of approach.
A common criticism of endovascular repair is that it may be less durable, requiring additional interventions to maintain limb salvage. 7, 15, 42, 43 We did identify an increased rate of subsequent intervention for endovascular procedures over the first 30 days. However, the differential between endo and open during this time period was only 7%. Moreover, beyond 30 days, the rate of subsequent intervention was identical for the 2 cohorts. Thus, at least over a 4-year period, the reintervention rate for endovascular procedures is only slightly increased compared with open revascularization.
Our results should be interpreted in the context of several limitations. First, anatomical characteristics are not available in this data set. Nevertheless, extant literature has demonstrated that clinical phenotypes for PAD correlate closely with the prevalence of specific patient comorbidities such as diabetes, 44, 45 renal failure, 46, 47 and critical limb ischemia. 48, 49 By matching these factors in our model, we feel that we have succeeded in matching patient anatomy. We are also unable to determine laterality of procedures, subsequent amputations, or subsequent interventions. We presume some percentage of amputations or subsequent procedures occurred in the contralateral extremity. Given the high likelihood that both groups had subsequent interventions on the contralateral extremity at approximately the same rate, the relative difference in the rates of subsequent interventions likely reflects the true discrepancy in reintervention rates. 42 Furthermore, undergoing a major amputation, regardless of side, indicates a failure of the procedure concurrent with the rationale previously described. 9 Finally, the generalizability of our analysis is limited to Medicare inpatients (although these represent the majority of patients undergoing lower extremity revascularization) 50 and is also limited to the population represented by endovascular patients who were matched. In performing a sensitivity analysis using alternative propensity score techniques, we found almost identical The model is additionally adjusted for race, eye disease, chronic blood loss anemia, rheumatoid arthritis or collagen vascular disease, complicated hypertension, obesity, benign tumor, Medicaid eligibility ever, hospital and patient rural urban commuting area, hospital type, origin of admission and year of procedure.
CHF indicates congestive heart failure; Endo, endovascular. results, suggesting that our estimates of treatment effect on the population studied are valid and reproducible.
CONCLUSIONS
Determining an optimal revascularization strategy for patients with symptomatic lower extremity PAD requires integration of surgeon and patient preferences, available resources, patient comorbidity, and relevant anatomy. Given availability of both endovascular and open revascularization options, we show that an endovascular approach is associated with improved long-term amputation-free survival. There is initially an increased risk of subsequent intervention after an endovascular procedure; however, this risk is modest and confined to the first 30 days after primary intervention. As always, the selection of interventions cannot be generalized and should be individualized for each patient based upon multiple factors and local expertise.
